Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103⁺ dendritic cells in late-stage ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Conejo-Garcia JR. Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Rev Obstet Gynecol 2012; 7:413-9; PMID:24039628; http://dx.doi.org/10.1586/eog.12.41
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366-72; PMID:20144842; http://dx.doi.org/10.1016/j.ygyno.2010.01.019
   PubMed Web of Science ®Google Scholar
• Lavoué V, Thédrez A, Levêque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V, Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013; 11:147; PMID:23763830; http://dx.doi.org/10.1186/1479-5876-11-147
   PubMed Web of Science ®Google Scholar
• Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008; 222:101-16; PMID:18363996; http://dx.doi.org/10.1111/j.1600-065X.2008.00614.x
   PubMed Web of Science ®Google Scholar
• Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-27; PMID:12684428
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161:1527-38; PMID:26073941; http://dx.doi.org/10.1016/j.cell.2015.05.025
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; PMID:12704383
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900-12; PMID:23975756; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550
   PubMed Web of Science ®Google Scholar
• Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011; 186:6905-13; PMID:21551365; http://dx.doi.org/10.4049/jimmunol.1100274
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/jem.20111413
   PubMed Web of Science ®Google Scholar
• Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008; 68:7684-91; PMID:18768667; http://dx.doi.org/10.1158/0008-5472.CAN-08-1167
   PubMed Web of Science ®Google Scholar
• Peter S, Bak G, Hart K, Berwin B. Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion. Transl Oncol 2009; 2:291-9; PMID:19956391; http://dx.doi.org/10.1593/tlo.09190
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE et al. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Cancer Res 2016; 76:239-50; PMID:26567141; http://dx.doi.org/10.1158/0008-5472.CAN-15-0748
   PubMed Web of Science ®Google Scholar
• Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI et al. Cancer immunotherapy with immunomodulatory Anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016; 6:71-9; PMID:26493961; http://dx.doi.org/10.1158/2159-8290.CD-15-0510
   PubMed Web of Science ®Google Scholar
• Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26:638-52; PMID:25446897; http://dx.doi.org/10.1016/j.ccell.2014.09.007
   PubMed Web of Science ®Google Scholar
• Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26:623-37; PMID:25446896; http://dx.doi.org/10.1016/j.ccell.2014.09.006
   PubMed Web of Science ®Google Scholar
• Dutertre CA, Wang LF, Ginhoux F. Aligning bona fide dendritic cell populations across species. Cell Immunol 2014; 291:3-10; PMID:25262488; http://dx.doi.org/10.1016/j.cellimm.2014.08.006
   PubMed Web of Science ®Google Scholar
• Schraml BU, Reis e Sousa C. Defining dendritic cells. Curr Opin Immunol 2015; 32:13-20; PMID:25553392; http://dx.doi.org/10.1016/j.coi.2014.11.001
   PubMed Web of Science ®Google Scholar
• Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
   PubMed Web of Science ®Google Scholar
• Hartung E, Becker M, Bachem A, Reeg N, Jäkel A, Hutloff A, Weber H, Weise C, Giesecke C, Henn V et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol 2015; 194:1069-79; PMID:25520399; http://dx.doi.org/10.4049/jimmunol.1401903
   PubMed Web of Science ®Google Scholar
• Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-91; PMID:10753190; http://dx.doi.org/10.1093/carcin/21.4.585
   PubMed Web of Science ®Google Scholar
• Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389-97; PMID:12649204
   PubMed Web of Science ®Google Scholar
• Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7:283-90; PMID:9285412; http://dx.doi.org/10.1016/S1074-7613(00)80530-0
   PubMed Web of Science ®Google Scholar
• Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008; 83:799-803; PMID:18063695
   PubMed Web of Science ®Google Scholar
• Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U S A 2012; 109:E3160-7; PMID:23093673; http://dx.doi.org/10.1073/pnas.1212753109
   PubMedGoogle Scholar
• Son M, Diamond B. C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1). Mol Med 2014; 20:559-68; PMID:25247291; http://dx.doi.org/10.2119/molmed.2014.00185
   PubMed Web of Science ®Google Scholar
• Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, Wasan PS, Wang XN, Malinarich F, Malleret B et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37:60-73; PMID:22795876; http://dx.doi.org/10.1016/j.immuni.2012.04.012
   PubMed Web of Science ®Google Scholar
• van der Aa E, van Montfoort N, Woltman AM. BDCA3(+)CLEC9A(+) human dendritic cell function and development. Semin Cell Dev Biol 2015; 41:39-48; PMID:24910448; http://dx.doi.org/10.1016/j.semcdb.2014.05.016
   PubMed Web of Science ®Google Scholar
• Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux AB, Combes J-D, Faget J, Mithieux F, Cassignol A, Tredan O et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 17:5423-34; PMID:21697280; http://dx.doi.org/10.1158/0008-5472.CAN-11-0367
   PubMed Web of Science ®Google Scholar
• Mayer CT, Ghorbani P, Nandan A, Dudek M, Arnold-Schrauf C, Hesse C, Berod L, Stüve P, Puttur F, Merad M et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 2014; 124:3081-91; PMID:25100743; http://dx.doi.org/10.1182/blood-2013-12-545772
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195-201; PMID:16500147; http://dx.doi.org/10.1016/j.it.2006.02.001
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; http://dx.doi.org/10.1038/nri3790
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36:265-76; PMID:25797516; http://dx.doi.org/10.1016/j.it.2015.02.008
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011; 30:141-51; PMID:21298574; http://dx.doi.org/10.1007/s10555-011-9289-9
   PubMed Web of Science ®Google Scholar
• Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 2009; 69:6331-8; PMID:19602595; http://dx.doi.org/10.1158/0008-5472.CAN-08-4329
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009; 69:7329-37; PMID:19738057; http://dx.doi.org/10.1158/0008-5472.CAN-09-0835
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009; 119:2231-44; PMID:19620771; http://dx.doi.org/10.1172/JCI37716
   PubMed Web of Science ®Google Scholar
• Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res 2015; 3:1257-68; PMID:26138335; http://dx.doi.org/10.1158/2326-6066.CIR-15-0044
   PubMed Web of Science ®Google Scholar
• Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 2015; 21:688-97; PMID:26121195; http://dx.doi.org/10.1038/nm.3883
   PubMed Web of Science ®Google Scholar
• Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003; 171:697-707; PMID:12847236; http://dx.doi.org/10.4049/jimmunol.171.2.697
   PubMed Web of Science ®Google Scholar
• Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol (Baltimore, Md: 1950) 2011; 187:1537-41; http://dx.doi.org/10.4049/jimmunol.1100660
   PubMed Web of Science ®Google Scholar